How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

593 results for

Androgenic Alopecia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

581. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. (PubMed)

Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. Androgenetic alopecia (male pattern hair loss) is caused by androgen-dependent miniaturization of scalp hair follicles, with scalp dihydrotestosterone (DHT) implicated as a contributing cause. Finasteride, an inhibitor of type II 5alpha-reductase, decreases serum and scalp DHT by inhibiting conversion of testosterone to DHT.Our purpose was to determine whether finasteride treatment

1998 Journal of the American Academy of Dermatology

582. Fluridil, a rationally designed topical agent for androgenetic alopecia: first clinical experience. (PubMed)

Fluridil, a rationally designed topical agent for androgenetic alopecia: first clinical experience. Fluridil, a novel topical antiandrogen, suppresses the human androgen receptor. While highly hydrophobic and hydrolytically degradable, it is systemically nonresorbable. In animals, fluridil demonstrated high local and general tolerance.To evaluate the safety and efficacy of a topical anti- androgen, fluridil, in male androgenetic alopecia.In 20 men, for 21 days, occlusive forearm patches with 2 (...) , 4, and 6% fluridil, isopropanol, and/or vaseline were applied. In 43 men with androgenetic alopecia (AGA), Norwood grade II-Va, 2% fluridil was evaluated in a double-blind, placebo-controlled study after 3 months clinically by phototrichograms, hematology, and blood chemistry including analysis for fluridil, and at 9 months by phototrichograms.Neither fluridil nor isopropanol showed sensitization/irritation potential, unlike vaseline. In all AGA subjects, baseline anagen/telogen counts were

2002 Dermatologic Surgery

583. Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. (PubMed)

Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. Hormone studies have demonstrated the androgen-dependent character of female androgenetic alopecia, but there have been few controlled studies of therapies for alopecia in women.To compare topical minoxidil 2% and cyproterone acetate in the treatment of female alopecia.Sixty-six women with female-pattern alopecia were randomly assigned for 12 cycles into two groups (...) index (BMI) revealed a borderline positive correlation in the cyproterone acetate group (r = 0.39, P = 0.06) and a negative correlation in the minoxidil group (r = -0.42, P < 0.05). No significant difference was observed in the total number of hairs among cyproterone acetate patients according to the presence or absence of other symptoms of hyperandrogenism, whereas in the minoxidil group, the total number of new hairs was higher in patients with isolated alopecia (Delta = 8.1; P < 0.05). Variations

2002 The British journal of dermatology

584. A randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-alpha-reductase in the treatment of androgenetic alopecia. (PubMed)

A randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-alpha-reductase in the treatment of androgenetic alopecia. Androgenetic alopecia (AGA) is characterized by the structural miniaturization of androgen-sensitive hair follicles in susceptible individuals and is anatomically defined within a given pattern of the scalp. Biochemically, one contributing factor of this disorder is the conversion of testosterone (T

2002 Journal of Alternative and Complementary Medicine

585. Shortness of breath: an uncommon side-effect of cyproterone acetate in the treatment of androgenetic alopecia. (PubMed)

of cyproterone acetate for biopsy proven androgenetic alopecia, who developed this unusual complication of shortness of breath. To our knowledge it has not been previously reported in women undergoing treatment for androgenization. (...) Shortness of breath: an uncommon side-effect of cyproterone acetate in the treatment of androgenetic alopecia. Cyproterone acetate is indicated for treatment of acne, hirsutism, seborrhea, and androgenetic alopecia in females. In general this medication is well tolerated in standard doses. Shortness of breath has been previously reported in men with prostatic carcinoma, receiving high-dose (200 mg/day) treatment with cyproterone acetate. We report a 66-year-old lady taking 50 mg/day

2002 International Journal of Dermatology

586. Male pattern androgenetic alopecia (Full text)

Male pattern androgenetic alopecia 9748188 1998 10 22 2018 11 13 0959-8138 317 7162 1998 Sep 26 BMJ (Clinical research ed.) BMJ Male pattern androgenetic alopecia. 865-9 Sinclair R R University of Melbourne, Department of Dermatology, St Vincent's Hospital, Victoria Parade, Melbourne 3065, Australia. sinclair@svhm.org.au eng Journal Article Review England BMJ 8900488 0959-8138 0 Androgens 0 Antihypertensive Agents 0 Enzyme Inhibitors 57GNO57U7G Finasteride 5965120SH1 Minoxidil AIM IM (...) Administration, Oral Administration, Topical Adolescent Adult Alopecia etiology pathology therapy Androgens physiology Antihypertensive Agents administration & dosage Enzyme Inhibitors administration & dosage Finasteride administration & dosage Hair transplantation Humans Male Minoxidil administration & dosage 36 1998 9 25 1998 9 25 0 1 1998 9 25 0 0 ppublish 9748188 PMC1113949 Am J Phys Anthropol. 1970 Jul;33(1):49-55 5431486 J Am Acad Dermatol. 1987 Mar;16(3 Pt 2):696-704 3549804 J Am Acad Dermatol. 1987

1998 BMJ : British Medical Journal PubMed

587. Variant 1859G→A (Arg620Gln) of the “Hairless” Gene: Absence of Association with Papular Atrichia or Androgenetic Alopecia (Full text)

Variant 1859G→A (Arg620Gln) of the “Hairless” Gene: Absence of Association with Papular Atrichia or Androgenetic Alopecia 11410842 2001 08 02 2018 11 13 0002-9297 69 1 2001 Jul American journal of human genetics Am. J. Hum. Genet. Variant 1859G-->A (Arg620Gln) of the "hairless" gene: absence of association with papular atrichia or androgenic alopecia. 235-7 Hillmer A M AM Kruse R R Betz R C RC Schumacher J J Heyn U U Propping P P Nöthen M M MM Cichon S S eng Letter United States Am J Hum (...) Genet 0370475 0002-9297 0 HR protein, human 0 Proteins 0 Transcription Factors IM Adolescent Adult Alopecia genetics Base Sequence Continental Population Groups genetics DNA Mutational Analysis Ethnic Groups genetics Exons genetics Female Gene Frequency genetics Genotype Haplotypes genetics Humans Male Middle Aged Mutation, Missense genetics Pedigree Point Mutation genetics Polymorphism, Genetic genetics Proteins chemistry genetics Transcription Factors Zinc Fingers genetics 2001 6 19 10 0 2001 8 3

2001 American Journal of Human Genetics PubMed

588. Essential oils and low-intensity electromagnetic pulses in the treatment of androgen-dependent alopecia. (PubMed)

Essential oils and low-intensity electromagnetic pulses in the treatment of androgen-dependent alopecia. This double-blind randomized study vs placebo in healthy male and female volunteers demonstrates the positive biologic effect on hair loss and hair regrowth of a pulsed electromagnetic field in combination with essential oils administered according to a regular treatment schedule of 26 weeks. Mean hair count comparisons within the groups significantly favor the treatment group, which

2003 Advances in therapy

589. Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. (PubMed)

Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. Use of 5 mg/day finasteride (Proscar) for benign prostatic hyperplasia is known to affect serum concentrations of prostate-specific antigen (PSA). When men taking this treatment undergo screening for prostate cancer, a compensatory adjustment of the PSA concentration (to multiply the value by two) is recommended. Whether this recommendation should (...) apply to men taking 1 mg/day finasteride (Propecia) for the treatment of androgenic alopecia is unknown. We aimed to assess the effect of 1 mg/day finasteride on serum PSA in men aged 40-60 years with male-pattern hair loss.Between March 13, 1998, and Jan 12, 2000, 355 men aged 40-60 years with male-pattern hair loss were stratified by age decade (40-49 years and 50-60 years), and randomised in a ratio of four to one to 1 mg/day finasteride or placebo. The primary endpoint was the effect

2007 The lancet oncology

590. Genetic variation in the human androgen receptor gene is the major determinant of common early-onset androgenetic alopecia. (Full text)

Genetic variation in the human androgen receptor gene is the major determinant of common early-onset androgenetic alopecia. Androgenetic alopecia (AGA), or male-pattern baldness, is the most common form of hair loss. Its pathogenesis is androgen dependent, and genetic predisposition is the major requirement for the phenotype. We demonstrate that genetic variability in the androgen receptor gene (AR) is the cardinal prerequisite for the development of early-onset AGA, with an etiological

2005 American Journal of Human Genetics PubMed

591. The E211 G>A androgen receptor polymorphism is associated with a decreased risk of metastatic prostate cancer and androgenetic alopecia. (Full text)

The E211 G>A androgen receptor polymorphism is associated with a decreased risk of metastatic prostate cancer and androgenetic alopecia. The androgen receptor (AR) gene encodes a transcription factor, which mediates androgen action in target tissues, including the prostate. Prostate cancer is androgen dependent, implicating AR in susceptibility to this male condition. Male pattern balding, androgenetic alopecia, has recently been associated with prostate cancer, suggesting shared androgen (...) pathways. The CAG and GGC repeats in the AR have been studied extensively as markers of prostate cancer susceptibility, with inconclusive findings, whereas the AR-E211 G>A polymorphism has been associated with androgenetic alopecia. We assessed the repeat linked single nucleotide polymorphism as a marker of risk association in prostate cancer, including androgenetic alopecia, in an Australian population-based case-control study. In 815 prostate cancer cases and 719 controls, the proportion of A-allele

2005 Cancer Epidemiology & Biomarkers and Prevention PubMed

592. A comparative study of a new food supplement, ViviScal, with fish extract for the treatment of hereditary androgenic alopecia in young males. (PubMed)

A comparative study of a new food supplement, ViviScal, with fish extract for the treatment of hereditary androgenic alopecia in young males. A controlled, randomized, double-blind, parallel-group study compared the effects of ViviScal (a new food supplement incorporating special marine extracts and a silica compound) with those of a fish extract in the treatment of young males with hereditary androgenic alopecia. The pretreatment histological diagnosis was alopecia with a mild to moderate (...) clinical or histological difference after 6 months' treatment (P < 0.0001). In both groups, a minimal decrease in the erythemal index was observed. In conclusion, ViviScal appears to be the first highly active treatment for androgenic alopecia in young males.

1992 The Journal of international medical research

593. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. (PubMed)

The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. Data suggest that androgenetic alopecia is a process dependent on dihydrotestosterone (DHT) and type 2 5alpha-reductase. Finasteride is a type 2 5alpha-reductase inhibitor that has been shown to slow further hair loss and improve hair growth in men with androgenetic alopecia.We attempted to determine the effect of finasteride on scalp skin and serum androgens.Men with androgenetic alopecia (N

1999 Journal of the American Academy of Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>